

REC Reference	IRAS Number	Name of Trial	Target number of patients agreed	Minimum number of patients agreed	Maximum number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number patients	Date Trial Closed to Recruitment	Total Number of Study Participants Recruited	Reason for Trial Closure
14/SC/1350	166544	CANC - 3619	Number agreed	3	3	Date agreed	01/03/2019	31/03/2019	3	Recruitment Finished
15/SC/0303	167788	CANC - 4432 - Revlimid (lenalidomide) NIS Post Authorization Safety Study (PASS)	Number agreed	1	1	Date agreed	31/12/2019	29/03/2019	2	Recruitment Finished
16/EM/0193	190690	CARD 4843	Number agreed	12	12	Date agreed	12/11/2018	12/11/2018	132	Recruitment Finished
16/NE/0384	209045	PARADISE-MI	Number agreed	5	5	Date agreed	03/01/2019	19/06/2019	9	Recruitment Finished
17/SC/0253	226685	MonarchE: Phase 3 Study of Abemaciclib in Breast Cancer (JPCF)	Number agreed	4	4	Date agreed	28/07/2019	15/02/2019	3	Withdrawn by sponsor
17/LO/1247	228533	Rova-T as 2nd Line Therapy (TAHOE)	Number agreed	2	2	Date agreed	29/01/2019	26/07/2018	0	Withdrawn by sponsor
17/LO/0438	217257	CLEAR Outcomes Study/1002-043	Number agreed	5	5	Date agreed	30/06/2019	03/06/2019	5	Recruitment Finished
17/WA/0420	235469	IRL790C003 Phase IIA Parkinson's Dykinesia Study	Number agreed	2	2	Date agreed	28/12/2018	31/05/2019	3	Recruitment Finished